Skip NavigationMarketsBusinessInvestingTechPoliticsVideoWatchlistInvesting Club
PRO
LivestreamMenuEvery weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks climbed on Monday after President Donald Trump announced a deal to end the U.S. and Iran war over the weekend. The S & P 500 was up 1.85%, on track for the index’s best day since April 8. The tech-heavy Nasdaq jumped more than 3%, headed for its best session since March 31. The 30-stock Dow hit a new all-time intraday high. Oil prices fell amid expectations that the Strait of Hormuz, a crucial global shipping channel for oil and gas, will soon reopen. The agreement between the U.S. and Iran, expected to be signed on Friday, would officially bring the four-month war to an end. Monday’s action follows a positive week for Wall Street , including the biggest IPO of all time in SpaceX on Friday. Shares gained 15% Monday after a 19% rise on Friday. Good to see that the additional stock supply isn’t pulling down the market. Health care was one of four sectors — along with energy, real estate, and staples — sitting out the market rally on Monday. The selling in health care, real Estate, and staples was a result of investors dumping defensive stocks to buy companies with more economic sensitivity. Also, drug stocks may be moving lower after the Centers for Medicare and Medicaid Services announced a new drug-price negotiation proposal. Analysts at RBC Capital flagged that the new proposal could pose headline risks for Johnson & Johnson , Bristol Myers , Merck , Regeneron , and other pharma stocks. Even though the drugmakers are out of favor once again and the group is vulnerable to give back some of last week’s gains as the market gravitates toward faster-moving stocks, one analyst published a positive note on a new J & J medicine that supports our long-term thesis. Analysts at Leerink said a survey of 56 dermatologists in the United States gave them greater confidence in their above-consensus sales forecast for psoriasis drug Icotyde for 2026 and 2027. According to the survey, roughly 75% of respondents reported having already been prescribed Icotyde, with most citing patient preference for an oral medication over an injectable method as the primary reason. This aligns exactly with our thesis that Icotyde, the first oral IL-23 inhibitor approved to treat moderate-to-severe plaque psoriasis, is well-positioned to gain share from similar injectables and existing oral treatments. In other company news, Johnson & Johnson said it is investing more than $1 billion in facilities in Jacksonville, Florida, to expand manufacturing for its Vision business. Salesforce is back in dealmaking mode , announcing it will acquire customer service platform Fin for $3.6 billion. Salesforce said Fin’s tools and models complement its Agentforce platform and will help Salesforce customers to more quickly launch AI-powered customer service agents and realize value. The deal is expected to close in the fourth quarter of Salesforce’s fiscal year 2027. Salesforce said it isn’t making any changes to its financial guidance and noted it won’t impact its capital return program, an important consideration because management is focused on reducing its share count. Analysts at Piper Sandler said buying Fin, formerly known as Intercom, makes sense as it “aims to solidify its role as an important AI partner in the enterprise and as it works to make Agentforce the dominant AI agent platform on the market.” Agentforce currently generates about $1.2 billion in annual recurring revenue. Salesforce shares were unable to hold their gains on Monday, extending a losing streak to 10 sessions. Clearly, the jury is still out on whether AI will be a friend or foe to Salesforce over the long term. There are no major earnings reports after the close on Monday or before the open on Tuesday, when May import prices, housing starts, and building permits will be released. (See here for a full list of the stocks in Jim Cramer’s Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.Read More
About The Author
